ASCT With Nivolumab in Patients With Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single center trial of Autologous Stem Cell Transplantation (ASCT)
with nivolumab in multiple myeloma patients to determine the efficacy and safety of ASCT and
PD1 inhibitor combination.
For this purpose, 30 multiple myeloma patients, who have received induction therapy and have
achieved a partial response (PR), stable disease (SD) or progression, and thus have
unfavorable prognosis, will be treated with nivolumab administered iv at a dose of 100 mg on
days 3 before and 17 after high-dose melphalan with autologous stem cell transplantation.